This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Edmondson, A. C. Articles by Rader, D. J. Search for Related Content PubMed Articles by Edmondson, A. C. Articles by Rader, D. J. Related Collections Genetics of cardiovascular disease Lipid and lipoprotein metabolism

Editorials

Genome-Wide Approaches to Finding Novel Genes for Lipid Traits

The Start of a Long Road

Andrew C. Edmondson, BS and Daniel J. Rader, MD

From the Cardiovascular Institute, Institute for Diabetes Obesity and Metabolism, and Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia.

Correspondence to Daniel J. Rader, MD, University of Pennsylvania School of Medicine, 654 BRBII/III Labs, 421 Curie Blvd, Philadelphia, PA 19104–6160. E-mail rader@mail.med.upenn.edu

Key Words: Editorials • genetics • lipids • lipoproteins

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The sequencing of the human genome and identification of common human genetic variations have made high-throughput interrogation of the human genome possible. Genome-wide association studies (GWASs) are now an exciting new approach to discovering the genetic variations underlying complex diseases and phenotypes.¹ These studies allow "hypothesis-free" interrogation of the entire genome without the biases of candidate gene approaches. The GWAS approach has both highlighted candidate genes previously identified by the study of mendelian disorders or by basic biological investigation and illuminated novel genomic loci clearly associated with the phenotype or disease of interest that were previously unsuspected. These studies are only the beginning of a shift in genetics and genomics that has the potential to alter our understanding of physiology and pathophysiology and to profoundly affect clinical medicine for generations to come. However, relatively few genes identified through GWASs have been rigorously assessed for their function in physiological processes, used for clinical risk assessment and prediction, or validated as bona fide targets for drug development.

Articles pp 10 and 21

The plasma lipid phenotypes of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides have been a fertile early testing ground for GWASs. They are quantitative heritable traits strongly associated with cardiovascular risk and widely measured in clinical practice, making them methodologically, clinically, and logistically attractive for investigation with genome-wide approaches. In the lipid GWASs reported to date, many genes previously identified with mendelian lipid disorders (Table 1) have been significantly associated with lipid phenotypes,^2–7 confirming that . . . [Full Text of this Article]